Summary latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H2 2020, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.
Pontine gliomas are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Pontine Glioma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 19, 12, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 5 and 1 molecules, respectively.
Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Ewing Sarcoma - Pipeline Review, H2 2020
Summary
latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2020, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.
Ewing’s sarcoma is a primary bone cancer that affects mainly...
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments. Targeted anticancer...
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
Gallbladder Cancer - Pipeline Review, H2 2020
Summary
latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2020, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.
Gallbladder cancer is a cancer that starts in...
Vaginal Cancer - Pipeline Review, H2 2020
Summary
latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2020, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.
Vaginal cancer is a rare cancer that occurs in vagina. Symptoms...
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures. With the increasing...
The global cold plasma equipment market is expected to reach US$ 308.87 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.6% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing...
Nanoscale technology is widely used in medical devices and medicine where manipulations are made at the molecular level, taking advantage of the novel properties of a material. The primary demand of this field in medicine is in making improvements in the delivery of treatments and healthcare outcomes. Nanomedicine refers to the usage of nanoscale...
Nanotechnology
Cancer
Infectious Disease
World
APAC
Middle East
Africa
Cancer Incidence
Mortality Rate
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.